10x Genomics entered into an agreement with PerkinElmer to advance next-generation sequencing (NGS) technology. The deal will combine the Chromium™ system from 10x Genomics with automation solutions from PerkinElmer.

“Our collaboration with PerkinElmer underscores 10x’s commitment to advancing the way we look at and understand genetic information,” said Serge Saxonov, co-founder and CEO, 10x Genomics. “As genomic research becomes more and more prominent, access to 10x solutions will illuminate a more comprehensive understanding of disease. By offering the Chromium System together with high-throughput automation platforms from PerkinElmer, we believe we will not only better serve our customers, we will also create a compelling workflow for meeting the research community’s critical need for long range, structural and cellular information.”

The Chromium system from 10x Genomics uses linked-read sequencing technology (which requires approximately 1 ng of DNA) to deliver long-range sequence information, perform haplotype phasing, and reveal structural genomic variation. According to a statement, PerkinElmer’s automation solutions increase both the throughput and efficiency of assays while also allowing researchers to streamline and enhance existing NGS workflows.

“This relationship with 10x Genomics will enhance the PerkinElmer automation menu and help progress researchers’ interpretation of some of the most important biological questions through increased sequence information and insights into the complexity of the genome,” said Prahlad Singh, senior vp and president, diagnostics, PerkinElmer. “The combination of 10x Genomics’ advanced technology and the precision automation provided by PerkinElmer’s portfolio will potentially enable a significant increase in sample numbers and elucidate important genomic variants that are associated with specific phenotypic traits or the progression of disease.”

Previous articleNatural Tooth Repair Stimulated by Alzheimer’s Drug
Next articleIBM and Illumina Team Up to Advance Precision Cancer Research